Stifel lowered the firm’s price target on Atara Biotherapeutics (ATRA) to $5 from $10 and keeps a Hold rating on the shares after the FDA has issued clinical holds for ATA3219 and Ebvallo. The firm believes a critical factor for Atara’s continued operation is to secure additional financing to support ATA3219, “as this is the most likely driver of future value.” Today’s announcement adds uncertainty around Atara’s catalysts, the analyst tells investors in a research note.
Maximize Your Portfolio with Data Driven Insights:
- Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions.
- Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ATRA:
- Atara Biotherapeutics downgraded to Neutral from Buy at Rodman & Renshaw
- Atara Biotherapeutics reports clinical hold placed on Ebvallo programs, ATA3219
- Atara Biotherapeutics price target lowered to $17 from $21 at Canaccord
- Atara Biotherapeutics trading resumes
- Atara Biotherapeutics remains eligible for $60M milestone payment